PRL and breast cancer: The JAK2-STAT3 and JAK2-STAT5 pathways have been demonstrated to be constitutively active in luminal breast cancer via the stimulation of IL-6 [87,88,89,90,91,92,93,94] and PRL [101,102,103], respectively.